Title: Elevated tumor expression of Astroprincin (FAM171A1) is an independent marker of
poor prognosis in colon cancer
Version: 2 Date: 30 May 2021
Reviewer's report:
1.In the main text file author did not mention the figure number (the result of
immunohistochemistry figure 1 A-D) and there is no scale bar in the figure.
2. Author should show the adjacent normal area and tumor area in the same tissue sample that
will be good control.
3. I have a big concern about the expression of APCN protein expression in tumors.
The TCGA database (http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl) and protein ATLS
database (https://www.proteinatlas.org/ENSG00000148468-FAM171A1/pathology/colorectal
+cancer#ihc) show low expression of APCN/FAM171A1 protein and survival rate is more in
APCN upregulated cancer patient. however, in this study, it has been shown that APCN protein
is upregulated in advanced cancer.
however, there are some reports which support this study. The author should discuss these points
in the discussion section.
4. In the method section (immunohistochemistry) the author does not mention about blocking
step.
5. to analyze the specificity of the antibody author should use the peptide as a competitive
inhibitor.
6.author should analyze the expression of the EMT marker (fibronectin/vimentin) in genetically
modulated APCN protein by siRNA or shRNA in colon cancer cells (Caco2 cells/HT29 cells/
HCT116 cells)
7.In the background section it has been written as 700.000 deaths, it should be 700,000 deaths.
Title: Elevated tumor expression of Astroprincin (FAM171A1) is an independent marker of
poor prognosis in colon cancer
Version: 2 Date: 30 May 2021
Reviewer's report:
1.In the main text file author did not mention the figure number (the result of
immunohistochemistry figure 1 A-D) and there is no scale bar in the figure.
2. Author should show the adjacent normal area and tumor area in the same tissue sample that
will be good control.
3. I have a big concern about the expression of APCN protein expression in tumors.
The TCGA database (http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl) and protein ATLS
database (https://www.proteinatlas.org/ENSG00000148468-FAM171A1/pathology/colorectal
+cancer#ihc) show low expression of APCN/FAM171A1 protein and survival rate is more in
APCN upregulated cancer patient. however, in this study, it has been shown that APCN protein
is upregulated in advanced cancer.
however, there are some reports which support this study. The author should discuss these points
in the discussion section.
4. In the method section (immunohistochemistry) the author does not mention about blocking
step.
5. to analyze the specificity of the antibody author should use the peptide as a competitive
inhibitor.
6.author should analyze the expression of the EMT marker (fibronectin/vimentin) in genetically
modulated APCN protein by siRNA or shRNA in colon cancer cells (Caco2 cells/HT29 cells/
HCT116 cells)
7.In the background section it has been written as 700.000 deaths, it should be 700,000 deaths.
Please review this paper.
user
Title: Elevated tumor expression of Astroprincin (FAM171A1) is an independent marker of
poor prognosis in colon cancer
Version: 2 Date: 30 May 2021
Reviewer's report:
1.In the main text file author did not mention the figure number (the result of
immunohistochemistry figure 1 A-D) and there is no scale bar in the figure.
2. Author should show the adjacent normal area and tumor area in the same tissue sample that
will be good control.
3. I have a big concern about the expression of APCN protein expression in tumors.
The TCGA database (http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl) and protein ATLS
database (https://www.proteinatlas.org/ENSG00000148468-FAM171A1/pathology/colorectal
+cancer#ihc) show low expression of APCN/FAM171A1 protein and survival rate is more in
APCN upregulated cancer patient. however, in this study, it has been shown that APCN protein
is upregulated in advanced cancer.
however, there are some reports which support this study. The author should discuss these points
in the discussion section.
4. In the method section (immunohistochemistry) the author does not mention about blocking
step.
5. to analyze the specificity of the antibody author should use the peptide as a competitive
inhibitor.
6.author should analyze the expression of the EMT marker (fibronectin/vimentin) in genetically
modulated APCN protein by siRNA or shRNA in colon cancer cells (Caco2 cells/HT29 cells/
HCT116 cells)
7.In the background section it has been written as 700.000 deaths, it should be 700,000 deaths.
assistant